S1P5 is in fact one of the targets of S1P receptor agonists such as fingolimod (FTY720), a drug approved to reduce aberrant accumulation of lymphocytes in patients suffering from autoimmune diseases such as multiple sclerosis (MS)49. This evidence concerns the gene S1PR5 and myeloid sarcoma.